NasdaqGS - Nasdaq Real Time Price ? USD argenx SE (ARGX) Follow Compare 605.92 +9.18 (+1.54%) At close: 4:00 PM EST 605.92 0.00 (0.00%) After hours: 4:08 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement. BioPharma Dive ? 12 hours ago HALO EVT.DE ARGX +1.54% argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease GlobeNewswire ? 2 days ago ARGNF ARGX +1.54% Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now? We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […] Insider Monkey ? 4 days ago ARGX +1.54% Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China SHANGHAI & CAMBRIDGE, Mass., November 11, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIDP Business Wire ? 11 days ago ZLAB +2.84% ARGNF ARGX +1.54% argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] GlobeNewswire ? 11 days ago ARGNF ARGX +1.54% Why Argenx (ARGX) Might be Well Poised for a Surge Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. Zacks ? 17 days ago ARGX +1.54% argenx to Participate at Upcoming Investor Conferences November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November: Guggenheim Inaugural Healthcare Innovation Conference. Fireside chat on Tuesday, November 12, 2024 at 2:30 p.m. ET in Boston, MA. Jefferies London Healthcare Conference. Manageme GlobeNewswire ? 17 days ago ARGNF ARGX +1.54% Three Value Stocks Priced Below Estimated Worth In November 2024 As global markets navigate a period of heightened economic activity and mixed signals from earnings reports, investors are keenly observing the performance of major indices, which have seen fluctuations amid busy data weeks. With value stocks showing resilience compared to their growth counterparts, this environment presents an opportunity to identify stocks that may be trading below their intrinsic worth. In such a climate, finding undervalued stocks requires a focus on strong fundamentals... Simply Wall St. ? 18 days ago ARGNF ARGX +1.54% GFL High Growth Tech Stocks To Watch In November 2024 In a week marked by busy earnings reports and economic data releases, global markets saw major indices like the Nasdaq Composite and S&P MidCap 400 hit record highs before retreating, while small-cap stocks showed resilience compared to their larger counterparts. Amidst this backdrop of cautious optimism and mixed signals from the labor market, investors are keenly watching high-growth tech stocks that demonstrate strong fundamentals and potential for innovation-driven expansion. Simply Wall St. ? 18 days ago TIPSMUSIC.BO TIPSMUSIC.NS ARGNF Argenx price target raised to $660 from $540 at Truist Truist raised the firm’s price target on Argenx (ARGX) to $660 from $540 and keeps a Buy rating on the shares after its Q3 earnings beat. The company delivered 11th consecutive sequential growth quarter and the stock offers the most enviable I&I – inflammation and immunology – pipeline in the industry, with multiple data read-outs over the next 12-18 months, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan TipRanks ? 20 days ago ARGNF ARGX +1.54% argenx SE (ARGNF) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Challenges argenx SE (ARGNF) reports robust product sales growth and a solid cash position, while navigating increased expenses and competitive market dynamics. GuruFocus.com ? 21 days ago ARGX +1.54% Here’s Why You Should Hold Argenx SE (ARGX) Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund appreciated 5.81%% (Institutional Shares) in the quarter compared to a 6.74% gain for the Russell 3000 Health Care Index (benchmark) and a 6.23% gain for the Russell […] Insider Monkey ? 22 days ago ARGX +1.54% argenx Reports Third Quarter 2024 Financial Results and Provides Business Update $573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET (8:30 AM ET) Regulated information - Inside information October 31, 2024 7:00AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced i GlobeNewswire ? 22 days ago ARGNF ARGX +1.54% argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at arg GlobeNewswire ? 29 days ago ARGNF ARGX +1.54% Discover October 2024's Stocks Estimated To Be Trading Below Fair Value As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, identifying stocks that may be trading below their fair value can offer potential opportunities for those looking to capitalize on market inefficiencies. Simply Wall St. ? last month CLLNY CLNXF NONOF Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return of 2.38%, and Institutional Class fund APHMX returned 2.40%, compared […] Insider Monkey ? last month ARGX +1.54% Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' PREMIUM MT Newswires ? last month ARGX +1.54% argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions Long-term and real-world data of VYVGART? (efgartigimod alfa-fcab) and VYVGART? Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-up safety data that totals >8,000 patient years; no vaccinations required and no impact on human serum albumin levels Real-world data show more than 50 percent of gMG patients demonstrate substantial and sustained reduction i GlobeNewswire ? last month ARGNF ARGX +1.54% argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... argenx SE (ARGNF) reports robust growth with $489 million in operating income, despite facing an operating loss and competitive pressures in the myasthenia gravis market. GuruFocus.com ? last month ARGX +1.54% Zacks.com featured highlights include Argenx SE Alphatec and Olin Argenx SE Alphatec and Olin have been highlighted in this Screen of The Week article. Zacks ? last month ARGX +1.54% OLN ATEC Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is BEL 20 Return ARGX BEL 20 YTD +59.27% +14.04% 1-Year +24.00% +20.27% 3-Year +113.37% -0.07%
